在ADMET和ADMET 2中测量临床相关的冷漠症状变化
Shankar Tumati1, Nathan Herrmann1, Jaime Perin2
1Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
International psychogeriatrics
|January 31, 2025
概括
研究人员确定了阿尔茨海默病 (AD) 患者无动于衷的临床重要差异最小值 (MCID). 这些发现有助于评估阿尔茨海默氏症患者对冷漠症状的治疗有效性.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 精神病学是一个精神病学.
背景情况:
- 漠不关心是阿尔茨海默病 (AD) 的常见和致残症状.
- 准确测量冷漠症症状严重程度对于评估治疗疗效至关重要.
- 最小临床重要差异 (MCID) 为患者报告结果的有意义变化提供了一个门.
研究的目的:
- 估计患有阿尔茨海默病的个人的冷漠症状严重程度的MCID.
- 为了比较三种验证的冷漠度评估尺度的MCID估计值.
主要方法:
- 追溯分析了"痴呆中的冷漠性甲基酸试验" (ADMET) 和ADMET 2的数据.
- 使用基于和基于分布的方法,以临床全局印象的变化在冷漠度作为.
- 使用线性混合模型,估计神经精神科目录的MCID - 无动于衷 (NPI-A),痴呆无动于衷访谈和评分 (DAIR) 和无动于衷评估量表-信息器 (AES-I).
主要成果:
- 估计的MCID是:在NPI-A上下降4个点,在DAIR上下降0.56个点,在AES-I上下降3个点.
- 基于和基于分布的分析产生了一致的结果.
- MCID估计显示了大约60%的准确性,基线冷漠度严重程度和MMSE得分影响了结果.
结论:
- 已建立的三级无动于衷的MCID可以帮助评估阿尔茨海默病患者在个人层面的治疗疗效.
- 在MCID和临床印象之间适度的协议强调了需要仔细解释和考虑多种评估工具的需要.
相关概念视频
Pharmacovigilance
769
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Alzheimer's Disease: Overview
437
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
437
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Phase II Reactions: Acetylation Reactions
169
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
169
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493


